Opportunistic Infections in Immunocompromised Patients *ACPE-Accredited*

Opportunistic infections represent a significant morbidity and mortality risk for severely immunocompromised patients, particularly those with untreated HIV. Modern antiretroviral therapy (ART) remains the primary strategy for prevention by restoring cellular immunity and reducing infection incidence. Clinical management requires monitoring CD4 T-helper cell counts to guide prophylactic and therapeutic interventions. For instance, Coccidioidomycosis screening is recommended for patients with CD4 counts below 250 in endemic regions, while Pneumocystis pneumonia (PCP) necessitates prophylactic Bactrim for those with counts below 200. Similarly, Toxoplasma gondii reactivation risks increase significantly when CD4 counts drop below 100, requiring targeted suppressive therapy. Effective treatment protocols often involve long-term antifungal or antibiotic regimens, necessitating careful oversight of drug-drug interactions, particularly with medications affecting liver enzymes or electrolytes, to ensure patient safety and therapeutic efficacy during immune recovery.